CT-1.5-SY26 - Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results (Includes Livestream)

Speaker(s):

• Lee Kaplan, MD, PhD, The Obesity and Metabolism Institute
• Matthias Tschöp, MD, Helmholtz Zentrum München